Porton Pharma Solutions Ltd.
博腾股份
300363
Shenzhen Stock Exchange
Company Profile
(1) A Global and End-to-End CDMO Platform to Meet Diverse Needs of Customers After 19 years of accumulation and evolution, the Company has established capabilities covering Small Molecule CDMO from starting materials to preparations, Synthetic Macromolecule CDMO such as peptides and oligonucleotides, Biological Macromolecule CDMO such as antibodies and ADCs, and Gene and Cell therapy CDMO, and provide a wide range of services from pre-clinical development through commercialization for different drugs and therapies. At the end of the reporting period, the Company has more than 20 Operating sites in China, the United States and Europe. The company's R&D technology platform is constantly maintaining its competitiveness through "faster innovation, centralized resources, improved efficiency, and keeping up with technological trends". Meanwhile, the Company's factory technology department has rich project experience and knowledge accumulation, and can provide professional services for customers to transfer projects from small-scale to commercialization. In addition, the Company also has professional engineering and technical capabilities to lay a solid foundation for building a highly flexible, internationally standardized manufacturing platform and improve manufacturing and operational efficiency. (2) Compliance Systems that Meet Global Standards, Overlaid with a Digital Empowerment Operating Management System The Company has established good reputation and delivery records in the industry, laying a solid foundation for the continuous development of new business. Our EHS management system, quality management system, as well as intellectual property and trade secret protection system are important cornerstones for the Company to maintain its leading position in the industry competition. Through digital empowerment, the Company proactively invests in quality reliability, cost optimization, engineering control, stable delivery, project management and other areas, to strengthen its core competitiveness. (3) Core Competitiveness as a ‘Pioneer’ Through 20 Years’ Experience in CDMO The Company provides services to hundreds of clients and projects each year. During the service process, the Company can engage deeply in the world's most advanced and complex pharmaceutical research and manufacturing, accumulating rich experience in the best practices and insights into the industry development. To date, the company has established business contacts with over 1,000 clients from the world's top 50 pharmaceutical companies, small and medium-sized pharmaceutical companies, and new drug development organizations of all types. Among the projects for which we have served, there are products that have been deeply bound for over ten years, potential reserve products that have been in service for two to three years, accompanying them from clinical phase one to phase two, and validation products obtained from customers due to technological advantages. Therefore, the Company has a relatively broad cooperation foundation, good delivery records, and brand image with global pharmaceutical companies and drug development organizations, which can provide more opportunities for the Company's future business development. (4) A Trustworthy Brand with the Corporate Culture of ‘Customer First, Pursuit of Excellence’ The Company has been implementing the service guidelines of ‘customer first, pursuit of excellence, constant innovation, and compliance’ in every customer service, constantly optimizing the customer experience. With more than 19 years of accumulation, the Company has established brand trust and influence among its major partners. In addition, the company continues to enhance market awareness and gain new customers' recognition through strengthening technology promotion.
Full description
Porton Pharma Solutions Ltd. (“the Company”) is a Contract Development and Manufacturing Organization (CDMO) that provides end-to-end services for pharmaceutical enterprises, biotech companies and research institutions globally, who can provide CDMO services for different types of drugs and therapies such as small molecule drugs, large molecule drugs and gene and cell therapy, includes: (1) Small Molecule API CDMO, primarily providing customers customized research and manufacturing services, including process route design, process development, process optimization, analytical method development, pilot plant production, CMC registration support, quality research and analysis development, and commercial production, for starting materials, intermediates, and APIs of chemical drugs; (2) Small Molecule Drug Product CDMO, mainly providing customers with customized research and manufacturing services, including formulation prescription process development and optimization, analytical method development and validation, complex formulation development, and improved dosage form development, for small molecule drug development; (3) Gene and Cell Therapy CDMO, mainly building CDMO platforms covered plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy, and live bacteria therapy and providing end-to-end services from library construction, process and analytical method development, cGMP production, to formulation filling; (4) Synthetic Macromolecules CDMO, mainly providing customized R&D and production services for multiple synthetic macromolecule drug fields such as peptides, oligonucleotides, coupled drugs (Linker, Payload) and drug delivery polymers;(5) Biological Macromolecules CDMO, which mainly provides end-to-end integrated CMC solutions for biological products such as antibody and antibody drug conjugate (ADCs) from preclinical development to commercialization. As of the end of the first half of 2025, the Company has provided services to over 1,300 clients and has a successful delivery record of over 4,600 projects. Our services cover treatment areas such as antivirals, anti-tumor and immune function regulation, anti-infection, neurological, cardiovascular, digestive and metabolic, and rare diseases.